Guardant Health, Inc. (GH) insider buying and selling

NASDAQ: GH · Source: SEC Form 4 filings · Latest trade reported

In the last 90 days at Guardant Health, Inc. (GH), no insider made an open-market purchase and 4 insiders made 13 open-market sales worth $24.8M, as reported on SEC Form 4. 1 of the 13 sales was scheduled in advance or made to cover tax on vesting shares, so they say less about the insider's view of the stock. Over the last 12 months, 1 insider bought $78K of the stock, led by Kumud Kalia (CIO), who bought $78K on Jun 15, 2026; 12 insiders sold $115.4M, of which $71.3M was scheduled or tax-related.

Insider buys, 90 days
0
$0 · 0 insiders
Insider sales, 90 days
13
$24.8M · 4 insiders
Insider buys, 12 months
1
$78K · 1 insider
Insider sales, 12 months
60
$115.4M · 12 insiders

This is the public summary. Create a free account to see GH’s AI Signal, the price chart with every insider trade plotted, and each insider’s track record.

Unlock GH

Recent open-market insider trades

Trades by the same insider within a week are shown as one line.

Open-market insider trades at Guardant Health, Inc.
DateInsiderTypeSharesPriceValue
AmirAli Talasaz
CEO
Open market sale
3 trades
37,500avg. $169.16$6.3M
Terilyn J. Monroe
Chief People Officer
Open market sale
5 trades
46,300avg. $165.12$7.6M
Chris Freeman
Chief Commercial Officer
Open market sale
4 trades
63,605avg. $169.58$10.8M
Kumud Kalia
CIO
Open market sale
4 trades
9,618avg. $130.42$1.3M
Kumud Kalia
CIO
Open market purchase600$130.76$78K
Helmy Eltoukhy
CEO
Open market sale
7 trades
100,000avg. $126.30$12.6M
Michael Brian Bell
CFO
Open market sale2,000$128.62$257K
Steve E. Krognes
Director
Open market sale9,294$132.51$1.2M
Medina Manuel Hidalgo
Director
Open market sale1,000$130.06$130K
Chris Freeman
Chief Commercial Officer
Open market sale24,406$118.67$2.9M
IAN T CLARK
Director
Open market sale6,876$106.90$735K
Medina Manuel Hidalgo
Director
Open market sale
2 trades
1,250avg. $107.09$134K

Scheduled and tax-related sales

Sales made under a pre-arranged 10b5-1 plan or to cover tax on vesting shares. They are listed separately because they are not a fresh decision to sell.

Scheduled and tax-related insider sales at Guardant Health, Inc.
DateInsiderTypeSharesPriceValue
Musa Tariq
Director
10b5-1 sale116$156.45$18K
Musa Tariq
Director
10b5-1 sale116$163.29$19K
AmirAli Talasaz
CEO
10b5-1 sale
6 trades
260,000avg. $151.20$39.3M
Musa Tariq
Director
10b5-1 sale
2 trades
2,067avg. $131.11$271K
MYRTLE S POTTER
Director
10b5-1 sale1,556$131.16$204K
John G. Saia
CLO
10b5-1 sale
5 trades
30,000avg. $112.70$3.4M
AmirAli Talasaz
CEO
10b5-1 sale
12 trades
210,000avg. $109.89$23.1M
Musa Tariq
Director
10b5-1 sale116$95.96$11K

What the GH insider trades really mean

The table above is the public summary. With an Insider Intel account you get the analysis behind it, for Guardant Health, Inc. and every other stock we track:

The AI Signal weighs:Insider buyingAnalyst ratingPrice upsideAI OutlookInsider track recordBreakout pressure

Plus AI summaries, the latest news for each stock, and an AI assistant you can ask questions about any of it.

Get started free with GH Insider Intel tracks insider activity at 3,154 companies right now. The Free plan includes full price charts and trade history, watchlists and email alerts.

Questions about GH insider trading

Who bought Guardant Health, Inc. (GH) stock recently?

Insiders who bought Guardant Health, Inc. stock on the open market in the last 12 months: Kumud Kalia ($78K). The most recent purchase was reported on Jun 15, 2026.

Are insiders buying or selling GH?

Over the last 12 months insiders were net sellers of GH on discretionary trades: $78K bought against $44.0M sold (scheduled and tax-related sales excluded).

What is a sell-to-cover or 10b5-1 sale?

A 10b5-1 sale is scheduled in advance under a pre-arranged plan, and a sell-to-cover sale is made to pay tax on vesting shares. Neither is a fresh decision to sell, so they say less about an insider's view than a discretionary sale.

Where does this data come from?

Officers, directors and large shareholders report their trades to the SEC on Form 4. This page lists the open-market purchases and sales by individual insiders from those public filings; funds and other institutions are not shown.

Other stocks with recent insider buying

Ready to see GH in full?

Create a free account and open its chart, score and alerts.

Create your free account

How to read this page

Officers, directors and large shareholders must report their trades in company shares to the SEC on Form 4. This page lists open-market purchases and sales by individual insiders: trades made on the stock exchange at the going price. Funds and other institutions are not shown here.

Information from SEC EDGAR Form 4 filings, shown for general information only. It is not financial advice and does not recommend buying or selling any security. Trades are shown by transaction date and may be reported up to two business days later.